N/A N=120 HIV And Parasitic Infection (HAPI) Study
HIV Coinfection
Primary: Number of Participants With and Without Intestinal Parasitic Infection — 36; 84 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=215 Incidence of HANA Conditions in HIV-infected Individuals
HIV · Metabolic Syndrome · Osteopenia
Primary: Prevalences of HIV-associated Non-AIDS Conditions (HANA) — 69; 15; 30; 4 Participants — p=0.244
N/A N=219 HIV-Tb Confections Among HIV Patients
HIV
Primary: Prevalence of HIV/Tb. co Infections Among Patients of HIV Enrolled at ART Center. — 48 participants
Phase 4 N=113 Anti-HIV Medications for People Recently Infected With HIV
HIV Infections
Primary: Total Treatment-free Time to Initiation of Permanent HAART — 18; 18 months
Phase 2 N=109 Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection
Infection · Precancerous Condition
Primary: Occurrence of ≥ Grade 3 Adverse Events Probably or Definitely Related to the Vaccine — 0 participants
Phase 4 N=182 Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults
Hepatitis B Vaccine
Primary: Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7 — 75; 69 Participants
Phase 2 N=319 Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
HIV Infections · Sexually Transmitted Diseases
Primary: Percentage of Participants With HPV6 Antibody Development From Seronegative Status at Baseline to Seropositive Status a Month After Completion of HPV Vaccination Series…
Phase 1 N=9 Single DermaVir Immunization in HIV-1 Infected Patients on HAART
HIV Infection
Primary: Grade 3 Adverse Event Related to DermaVir Treatment — 0; 0; 0 participants
N/A N=114 Effects of Mindfulness Training on Chronic Inflammation in HIV-Infected Adults
HIV
Primary: Interleukin 6 (IL-6) Biological Markers — 2.24; 2.63; 2.53; 2.88 pg/mL
N/A N=30 HIV-related Insomnia and Inflammation
Hiv · Insomnia
Primary: Change in hsCRP Levels at 24 Weeks — 2.19; 4.47 mg/L — p=0.607
Phase 4 N=546 Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Infections, Papillomavirus · Papillomavirus Vaccines
Primary: Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms — 115; 58; 4; 0 Participants
Phase 2 N=33 Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus
Anal Cancer · Precancerous Condition
Primary: Proportion of Patients With Regression of Perianal High-grade Squamous Intraepithelial Lesions (HSIL) — 0.515 proportion of participants
Phase 2 N=7 Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy
HIV Infection
Primary: Pre- and Post- Interferon Alpha on Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) — 670; 180; 90; 130 # of copies of HIV RNA/million cells
Phase 3 N=91 Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions
Anal Intraepithelial Neoplasia · High-grade Squamous Intraepithelial Lesion · HIV Infection
Primary: Percentage of Participants Achieving Complete Response in 5-FU Arm and Observation Arm Using ITT Population — 5; 9 Participants — p=0.1877
Phase 2 N=14 A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults
HIV Infections
Primary: Part 1: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Day 11 — -8605.8; -100719.8; -3406.5 Copies per milliliter
N/A N=172 Durability of Adherence in Self-Management of HIV
HIV Infections
Primary: Mean Self-reported Adherence Score (%) Over a One-month Recall — 97.5; 98.2 percentage of adherence score — p=0.52
Phase 2 N=149 Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
Anal Cancer · Nonneoplastic Condition · Penile Cancer
Primary: Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 6 DNA — 0.0; 11.1 Events per 100 person years — p=0.112
Phase 2 N=231 Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected Subjects
Polio Immunity
Primary: Post Booster Polio Neutralizing Antibody Titers — 1715; 976; 1249; 1328 antibody titers
Phase 3 N=271 Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients
Human Papilloma Virus · Hiv · Organ Transplants
Primary: Seroconversion Following 3 Doses of 9-valent HPV Vaccines — 100; 64.2; 100; 70.7 Percentage of participants
N/A N=143 Pain and Sensory Changes Assessment in HIV+ Patients
HIV Infections
Primary: Number of Participants With Chronic Myogenic Pain, TMJ Disoder, and Burning Mouth Syndrome — 72; 8; 37; 7 Participants
N/A N=8,202 HIV Cohort Study At Johns Hopkins University, University of North Carolina at Chapel Hill and Vanderbilt University
HIV · AIDS
Primary: Incidence Rate of Malignancies — 0.30; 0.27; 0.02; 0.62 malignancies per 100 person-years
N/A N=164 Information Visualizations to Enhance HIV-related Communication
HIV · Communication Research
Primary: Change in CD4 Count Over Time — 446.71; 453.99; 498.04; 537.90 Cells/mm3 — p=.455
Phase 2 N=58 ARVs to Prevent Breastmilk HIV:Viral and Immune Responses
HIV Infections
Primary: Outcome 1: Serial HIV-1 RNA Levels in Breastmilk. — 2.74; 2.03; 1.70; 1.70 Log10 Viral load copies/ml
Phase 1 N=23 A Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB0115-00-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults
HIV
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Product Administration — 3; 2; 2; 3 Participants
N/A N=250 Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
HIV Infections · Memory
Primary: The Prevalence of Neurocognitive Deficits Among HIV-positive Patients as Defined by the Global Deficit Score Based on the Neuropsychological Testing Battery and to…
Phase 3 N=407 Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)
Pneumococcal Infections
Primary: Percentage of Participants With a Solicited Injection-Site Adverse Event Following Vaccination With V114 or Prevnar 13™ — 9.4; 5.9; 10.3; 6.4 Percentage of Participants
Phase 1 N=23 HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease
Aids, Cdc Group I
Primary: Tolerability and Safety of the Treatment. — 0; 0 participants
Phase 1 N=26 VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults
HIV Prevention
Primary: Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 3 Days of Any Product Administration — 3; 3; 3; 2 Participants
N/A N=282,368 Kaiser Permanente HIV Cohort Study
HIV · AIDS
Primary: Incidence Rate of Malignancies — 513; 3; 238; 20 malignancies per 100,000 person-years — p=<0.001
N/A N=175 Incidence and Prevalence of Cancer in People Living With HIV/AIDS at Cancer Centers in Latin America
HIV Infection · Human Immunodeficiency Virus 1 Positive · Malignant Neoplasm
Primary: Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at…